Recurrence · Adults with oral cavity or oropharyngeal cancer
The review found no eligible studies for this question.
1 finding from 1 review
Locoregional recurrence · Adults with oral cavity or oropharyngeal cancer
1 finding from 1 review
Locoregional recurrence: reported difference between groups not statistically significant (P=0.355), but no useable data; 32 participants (1 RCT, Iyer 2015).
1 study · 32 participants
Very low
Oral mucositis (moderate to severe) · Adults receiving chemotherapy alone for colorectal cancer
Intestinal trefoil factor (ITF), oral spray led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Dry mouth (xerostomia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol showed no clear difference in xerostomia (dry mouth, yes/no) compared with artificial saliva; GRADE not reported.
2 findings from 1 review
Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol led to higher salivary flow rate (unstimulated, ml/min) compared with artificial saliva; GRADE not reported.
2 findings from 1 review
Progression‐free survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Palifermin showed no clear difference in progression-free survival compared with placebo; GRADE not reported.
1 finding from 1 review
HR 1.06 [0.80, 1.42]
3 studies
GRADE not reported
Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol showed no clear difference in overall survival compared with artificial saliva; GRADE not reported.
1 finding from 1 review
Dysphagia (grade >= 3, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in dysphagia (grade >= 3, 0-4 scale) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Chinese medicine led to higher salivary flow rate (stimulated) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Xerostomia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Palifermin showed no clear difference in xerostomia (grade >= 2, 0-4 scale) compared with placebo (low certainty).
1 finding from 1 review
Drooling (hyposialosis) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Antiseptic mouthrinse showed no clear difference in drooling (hyposialosis) compared with placebo; GRADE not reported.
1 finding from 1 review
Quality of life (McMaster HNRQ, 1-7 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether pilocarpine changes quality of life (McMaster HNRQ, 1-7 scale) compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Disease-free survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in disease-free survival compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in quality of life compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether amifostine changes salivary flow rate (mg/5 min, unstimulated) compared with no treatment/placebo (very low certainty).
2 findings from 1 review
Progression‐free survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in progression-free survival compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review